Free shipping on all orders over $ 500

GSK2636771

Cat. No. M2050
GSK2636771 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 150 In stock
50mg USD 350 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

GSK2636771 is a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kβ) for the treatment of PTEN deficient tumors. GSK2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK2636771 decreases phosphorylated protein kinase Akt (Ser473) levels in these xenograft models. GSK2636771 (100 mg/kg) do not increase glucose/insulin levels in mice. GSK2636771 is currently in Phase I/II trials.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Cell (2015). Figure 3. GSK2636771 (Abmole)
Method Tumor growth assay
Cell Lines
Concentrations 30mg/kg per oral gavage daily
Incubation Time 21 days
Results Both BYL719 and GSK2636771, a structurally unrelated p110b inhibitor currently in clinical trials, slowed tumor growth but only the combination induced tumor shrinkage.
Source Cancer Cell (2015). Figure 3.GSK2636771 (Abmole)
Method Immunoblotting
Cell Lines BT-474, SKBR3 cell
Concentrations 1µM
Incubation Time 24 h
Results This led to the loss of p110b recruitment and the block of the rebound of AKT activation observed 24 hr after treatment with BYL719 alone.
Protocol
Cell Experiment
Cell lines EEC cell lines
Preparation method Cells were plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/ well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24h, cells were treated with serial dilutions (100pM to 10μM) of PI3K and MAPK pathway inhibitors (Supplementary Methods, Supplementary Table 3). Cell viability was assessed after 72h of treatment by incubation with CellTiter Blue (Promega, Southampton, UK) for 1.5h.
Concentrations 100pM to 10μM
Incubation time 72h
Animal Experiment
Animal models 6- to 8-week-old female athymic nude mice BT474 tumor model
Formulation GSK2636771 was dissolved on 0.5% metilcellulose and 0.2% Tween 80.
Dosages 30mg/kg daily
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 433.42
Formula C22H22F3N3O3
CAS Number 1372540-25-4
Purity >99%
Solubility DMSO 80 mg/mL
Storage at -20°C
Related PI3K Products
PIK-III

PIK-III (also known as VPS34-IN2) is a potent and selective inhibitor of VPS34 enzymatic activity, with IC50s of 18 nM and 1.2 μM for VPS34 and PI(3)Kδ, respectively.

LY3023414

LY3023414 is a selective ATP-competitive inhibitor of PI3Kα and mTOR, DNA-PK, and other class I PI3K family members.

SAR405

SAR405 is a PIK3C3/Vps34 inhibitor with an IC50 of 1.2 nM. SAR405 also is a proximal inhibitor of the autophagy machinery.

Tenalisib

Tenalisib (RP6530) is a potent and selective dual PI3Kδ/γ inhibitor with IC50 values of 24.5 nM and 33.2 nM for PI3Kδ and PI3Kγ, respectively. Its selectivity over α and β isoforms are more than 300-fold and 100-fold, respectively.

PI 828

PI 828 is a pI 3-kinase inhibitor, more potent than LY 294002.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: GSK2636771 supplier, PI3K, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.